Novel male hormonal contraceptive combinations: The hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5α-reductase inhibitor or gonadotropin-releasing hormone antagonist

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 1, 2005, Pages 91-97

  Matthiesson, Kati L ^a,d   Amory, John K ^b   Berger, Richard ^b   Ugoni, Antony ^c   McLachlan, Robert I ^a   Bremner, William J ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLINE; ANDROGEN; DUTASTERIDE; GESTAGEN; GONADORELIN ANTAGONIST; GONADOTROPIN; LEVONORGESTREL; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; AZOOSPERMIA; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG SYNTHESIS; GONADOTROPIN BLOOD LEVEL; HUMAN; MALE; MALE FERTILITY; OLIGOSPERMIA; PRIORITY JOURNAL; SPERMATOGENESIS; SPERMATOZOON DENSITY; TESTOSTERONE BLOOD LEVEL;

ADULT; CHOLESTENONE 5 ALPHA-REDUCTASE; CONTRACEPTIVE AGENTS, MALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; SPERM COUNT; SPERMATOGENESIS; TESTOSTERONE;

ILEX COOKII;

EID: 12244267983     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1228     Document Type: Article

References (45)

1. 2002 Hormonal contraception: what is new? Hum Reprod Update 8:359-371
2. Trussell J, Kost K 1987 Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 18:237-283
3. Anawalt BD, Amory JK 2001 Advances in male hormonal contraception. Ann Med 33:587-595
4. 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Lancet 336:955-959
5. 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821-829
6. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY 2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562-568
7. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ 2003 Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659-4667
8. Robertson DM, Pruysers E, Stephenson T, Pettersson K, Morton S, McLachlan RI 2001 Sensitive LH and FSH assays for monitoring low serum levels in men undergoing steroidal contraception. Clin Endocrinol (Oxf) 55: 331-339
9. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA 1996 Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 81:4113-4121
10. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C 2004 Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 89:142-149
11. Pavlou SN, Brewer K, Parley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM 1991 Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73:1360-1369
12. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Herman N, Steiner B, Bremner WJ 1998 Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 83:3527-3533
13. Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS 1992 Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab 75:476-483
14. Herbst KL, Anawalt BD, Amory JK, Bremner WJ 2002 Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 87:3215-3220
15. Kamischke A, Nieschlag E 2004 Progress towards hormonal male contraception. Trends Pharmacol Sci 25:49-57
16. McLachlan RI, O'Donnell L, Stanton PG, Balourdes G, Frydenberg M, de Kretser DM, Robertson DM 2002 Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 87:546-556
17. O'Donnell L, Stanton PG, Wreford NG, Robertson DM, McLachlan RI 1996 Inhibition of 5α-reductase activity impairs the testosterone-dependent restoration of spermiogenesis in adult rats. Endocrinology 137:2703-2710
18. O'Donnell L, Pratis K, Stanton PG, Robertson DM, McLachlan RI 1999 Testosterone-dependent restoration of spermatogenesis in adult rats is impaired by a 5α-reductase inhibitor. J Androl 20:109-117
19. Kinniburgh D, Anderson RA, Baird DT 2001 Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl 22:88-95
20. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW 2000 Efficacy and acceptability of testosterone implants, alone or in combination with a 5α-reductase inhibitor, for male hormonal contraception. Contraception 62:73-78
21. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G 2002 Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434-441
22. World Health Organization 1999 WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 4th ed. Cambridge, UK: Cambridge University Press
23. Rivier JE, Jiang G, Porter J, Hoeger CA, Craig AG, Corrigan A, Vale W, Rivier CL 1995 Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. J Med Chem 38:2649-2662
24. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM 1999 A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20:407-414
25. Anderson RA, Wu FC 1996 Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 81:896-901
26. Herbst KL, Anawalt BD, Amory JK, Matsumoto AM, Bremner WJ 2003 The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. J Clin Endocrinol Metab 88:1167-1173
27. Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ 1999 Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84:112-122
28. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ 1993 Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab 77:427-432
29. Bagatell CJ, McLachlan RI, de Kretser DM, Burger HG, Vale WW, Rivier JE, Bremner WJ 1989 A comparison of the suppressive effects of testosterone and a potent new gonadotropin-releasing hormone antagonist on gonadotropin and inhibin levels in normal men. J Clin Endocrinol Metab 69:43-48
30. Zhang FP, Pakarainen T, Poutanen M, Toppari J, Huhtaniemi I 2003 The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc Natl Acad Sci USA 100:13692-13697
31. Amory JK, Anawalt BD, Bremner WJ, Matsumoto AM 2001 Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development. J Androl 22:1053-1060
32. Handelsman DJ, Parley TM, Peregoudov A, Waites GM 1995 Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 63:125-133
33. Anderson RA, Wallace AM, Wu FC 1996 Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5α-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab 81:902-908
34. Anderson RA, Kelly RW, Wu FC 1997 Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. V. Localization of higher 5α-reductase activity to the reproductive tract in oligozoospermic men administered supraphysiological doses of testosterone. J Androl 18:366-371
35. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E 2001 Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J Clin Endocrinol Metab 86: 2585-2590
36. McLachlan RI, O'Donnell L, Meachem SJ, Stanton PG, de Kretser DM, Pratis K, Robertson DM 2002 Identification of specific sites of hormonal regulation in spermatogenesis in rats, monkeys, and man. Recent Prog Horm Res 57: 149-179
37. Ishimaru T, Edmiston WA, Pages L, Horton R 1978 Splanchnic extraction and conversion of testosterone and dihydrotestosterone in man. J Clin Endocrinol Metab 46:528-533
38. Santner SJ, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, Demers LM, Shackleton C, Santen RJ 1998 Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 83:2104-2109
39. Weinstein RL, Kelch RP, Jenner MR, Kaplan SL, Grumbach MM 1974 Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 53:1-6
40. Kelch RP, Jenner MR, Weinstein R, Kaplan SL, Grumbach MM 1972 Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome. J Clin Invest 51:824-830
41. Rittmaster RS, Lemay A, Zwicker H, Capizzi TP, Winch S, Moore E, Gormley GJ 1992 Effect of finasteride, a 5α-reductase inhibitor, on serum gonadotropins in normal men. J Clin Endocrinol Metab 75:484-488
42. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E 1992 Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74:505-508
43. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S 2004 Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 89:2179-2184
44. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS 1982 Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425-430
45. Schurmeyer T, Nieschlag E 1984 Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7:181-187